Liberum Capital reissued their hold rating on shares of Shire (LON:SHP) in a research note released on Tuesday, November 14th. The brokerage currently has a GBX 4,200 ($56.25) price objective on the biopharmaceutical company’s stock.
A number of other research firms also recently weighed in on SHP. Shore Capital reaffirmed a buy rating on shares of Shire in a research note on Wednesday, July 19th. J P Morgan Chase & Co reissued an overweight rating on shares of Shire in a report on Thursday, July 20th. Credit Suisse Group reiterated an outperform rating and issued a GBX 5,350 ($71.65) price objective on shares of Shire in a research report on Friday, August 4th. Deutsche Bank reissued a buy rating and issued a GBX 6,000 ($80.35) target price on shares of Shire in a research note on Friday, August 4th. Finally, Beaufort Securities restated a long term buy rating and issued a GBX 4,900 ($65.62) price objective (down previously from GBX 6,200 ($83.03)) on shares of Shire in a research note on Friday, August 4th. Four investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of GBX 5,277.78 ($70.68).
Shire (LON SHP) traded down GBX 2.84 ($0.04) during mid-day trading on Tuesday, hitting GBX 3,658.66 ($49.00). The company had a trading volume of 1,480,000 shares, compared to its average volume of 2,830,000. Shire has a twelve month low of GBX 3,435.50 ($46.01) and a twelve month high of GBX 5,067 ($67.86).
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.